Biotech
Aug. 11, 2011
Seth D. Levy
Levy said he's excited about working with companies involved in leading-edge science, but there are challenges - political as well as scientific.
Consider the ongoing controversy over how stem-cell research should be funded.
"If the main source of funding isn't here," Levy said, "people do go elsewhere - to Singapore, the United Kingdom and Israel - where they don't have the same obstacles."
Therapeu...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In